You can buy or sell FLGT and other stocks, options, ETFs, and crypto commission-free!
Fulgent Genetics, Inc. Common Stock, also called Fulgent Genetics, is a technology company, which focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Read More Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
Temple City, California
52 Week High
52 Week Low
Simply Wall StMar 13
Does Fulgent Genetics, Inc. (NASDAQ:FLGT) Have A Volatile Share Price?
If you’re interested in Fulgent Genetics, Inc. (NASDAQ:FLGT), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the port...
Stock Price, News, & Analysis for Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, C...
Seeking AlphaMar 2
Fulgent Genetics' (FLGT) CEO Ming Hsieh on Q4 2018 Results - Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Nicole Borsje – Head of Investor Relations Ming Hsieh – Chief Executive Officer Paul Kim – Chief Financial Officer Conference Call Participants Bill Quirk – Piper Jaffray Erin Wright – Credit Suisse Operator Good day, ladies and gentlemen, and welcome to the Fulgent Genetics Fourth Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be...
Expected May 6, After Hours